wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (639)	3/26/1999 8:19:00 PM
From: SeachRE	Read Replies (1) of 942

Shares are down 20% from highs. Does Rezulin account for 20% of earnings?I doubt it. I speculate that Rezulin is actually a fairly expensive drug to make, just by looking at its molecular structure.Additionally, earnings still have to be shared with Sankyo. According to basic science work,Pioglitazone(Actos) appears inferior to Rezulin as an anti-diabetic.I do not know about SBH's Avandia,though.Head-to-head clinical comparisons do not exist,to my knowledge. Anyhow,the market's over-reaction lead to a welcome buying opportunity.Growth at 25+% longterm,means a possible double in 3 years ( 70/25=2.8 ).Just one man's opinion.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next